Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
To study the 2-year PFS (progression-free survival) of patients with stage II-III
nasopharyngeal carcinoma of pretreatment EBV DNA<4000 copy/ml treated with induction
chemotherapy followed by two different doses of intensity modulated radiation therapy plus
concurrent cisplatin chemotherapy